CALL - SPRINTER OPEN END - VERTEX PHARMACEUTICALS | Market Closed - Deutsche Boerse AG 19:04:38 20/06/2024 BST | ||
| 17.81 EUR | +4.03% |
|
| Current month | +13.22% | ||
| 1 month | +15.57% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 20/06/24 | 17.81 | +4.03% |
| 19/06/24 | 17.12 | -2.12% |
| 18/06/24 | 17.49 | -3.80% |
| 17/06/24 | 18.18 | -2.62% |
| 14/06/24 | 18.67 | +1.58% |
Delayed Quote Deutsche Boerse AG
Last update June 20, 2024 at 07:04 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VU8GF7 |
| ISIN | DE000VU8GF73 |
| Date issued | 13/06/2023 |
| Strike | 284.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 7.78 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 18.9 € |
|---|---|
| Lowest since issue | 6.86 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
471.4
USD
Average target price
463.4
USD
Spread / Average Target
-1.69%
- Stock Market
- Certificates
- Certificat
